← Back to results

J Gastroenterol Hepatol · 2022

Patient-derived cancer organoids for drug screening: Basic technology and clinical application.

Journal of gastroenterology and hepatology, 37(8): 1446-1454 PMID 35771719 DOI 10.1111/jgh.15930

Open in PubMed ↗ Open via DOI ↗

Abstract

Cancer organoids, a three-dimensional (3D) culture system of cancer cells derived from tumor tissues, recapitulate physiological structure of the parental tumor. Different tumor organoids have been established for a variety of tumor types, such as colorectal, liver, stomach, pancreatic and brain tumors. Some tumor organoid biobanks are built to screen and discover novel antitumor drug targets. Moreover, patients-derived tumor organoids (PDOs) could predict treatment response to chemoradiotherapy, targeted therapy and immunotherapy to provide guidance for personalized cancer therapy. In this review, we provide an updated overview of tumor organoid development, summarize general approach to establish tumor organoids, and discuss the application of anti-cancer drug screening based on tumor organoid and its application in personalized therapy. We also outline the opportunities and challenges for organoids to guide precision medicine.

Cite